No description available.

Inflammatory Bowel Diseases (IBD) result from the nexus of a genetic predisposition, dysregulated immunologic insult against commensal microflora, and an environmental trigger. The intestinal epithelium is a single cell layer that separates a highly active mucosal immune system from a large antigenic load in the intestinal lumen. Innate immune recognition combined with a highly regulated adaptive immune response maintains this tolerance. The intestinal epithelium in collusion with antigen presenting cells primarily modulates this activity. In this thesis, we show that, in response to DNA isolated from bacteria, innate toll like receptor 9 (TLR9) activation in intestinal epithelial cells modulates both arms of the immune system, to regulate intestinal homeostasis, and through this mechanism, Bifidobacteria breve DNA exerts its anti-inflammatory function. / Experimental Medicine

La polyarthrite rhumatoïde (PR) est une maladie auto-immune inflammatoire. La PR touche les articulations jusqu'à les détruire. Elle est caractérisée par la présence d’anticorps anti protéines citrullinées (ACPA) mais l’auto-antigène n’est toujours pas connu. Dans cette maladie, l’implication de l’immunité adaptative ne fait donc aucun doute mais le rôle de l’immunité innée reste encore flou. Le système du complément joue un rôle important dans l’immunité innée tout comme les récepteurs de type Toll (TLR) qui sont des récepteurs de celle-ci. C1q, par la reconnaissance des ses ligands, active une des voies du complément, la voie classique. Chez les patients atteints de PR, le complément est activé et un dépôt de C1q est retrouvé dans l’articulation. Le TLR9 reconnaît des ADN dérivés de bactéries ou de virus mais une expression à la surface des cellules pourrait conduire à la reconnaissance d’autres motifs comme les signaux de danger (DAMP). D’ailleurs, nous avons montré récemment qu’il existait un TLR9 exprimé à la surface des polynucléaires neutrophiles (PNN). Enfin, il a été mis en évidence récemment un nouveau mécanisme bactéricide effectué par les PNN : la formation de NET (neutrophil extracellular traps). Mais en dehors de leur rôle bactéricide, les NET ont été montrés comme pathogènes dans certaines maladies comme le lupus. Dans ce travail de thèse, je me suis intéressé à l’implication de ces acteurs, NET, C1q et TLR9 dans la PR. Nous avons montré que C1q est indispensable au développement de l’arthrite dans un modèle animal. De plus, l’expression des récepteurs au C1q par les PNN et les monocytes est corrélée à l’activité de la maladie et à l’inflammation. Nous avons montré que les NET représentent une cible pour les ACPA (ce qui en fait des auto-antigènes potentiels dans la PR) et que ces NET sont immunogènes. L’immunogénicité des NET est modulée par C1q. Enfin, il semblerait que le TLR9 ait moins d’importance dans l’arthrite. Par ce travail, nous avons montré l’importance du rôle joué par l’immunité innée dans la PR et ses modèles. / Rheumatoid artthritis (RA) is the most frequent rheumatic disease. This auto-immune disease causes pain and joint destruction. RA has been characterized by adaptative immunity involvement and anti-citrullinated protein antibodies (ACPA) production. Involvement of innate immunity is less investigated. Complement system, part of innate immunity, is activated in RA. C1q activates classical complement pathway by binding its ligands. C1q is found in joint of RA patients. On the other hand Toll-like-receptor (TLR), innate receptors could play a role in RA upon recognition of pathogen-derived DNA (TLR9). Cell surface expression of TLR9 has been reported as potentially pathological, and we describe that polymorphonuclear neutrophils (PMN) express a cell surface TLR9 wich could recognize damage associated molecular pattern (DAMP). Finally, neutrophil extracellular traps (NET) wich are expelled chromatin fiber and represent a physiological response to bacteria, have been reported as pathological in certain circumstances. We investigated the role of those three innate actors in RA. We have shown that C1q is mandatory to develop experimental arthritis and expression of their receptors on RA patient PMN and monocytes is correlated with disease activity and inflammation. We have also shown that NET are immunogenic and this immunogenicity is partly modulated and mediated by C1q. NET might trigger ACPA production in RA. Finally, it seems that involvement of TLR9 is less important in RA. With those experiments we have shown that the involvement of innate immunity in RA is more important than that has been reported so far.

Objectives: Mental and physical stress can suppress the immune system in both humans and animals. The mechanism by which stress affects immune responses, however, remains poorly defined. Toll-like receptors (TLRs) play a key role in modulating immune responses and cell survival. The mechanisms by which TLRs modulate chronic stress are largely unexplored. Methods: Six- to 8-week-old male mice were subjected to chronic 12-hour daily physical restraint stress. Apoptotic cells were determined by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. We examined cytokine levels by enzyme-linked immunosorbent Assay (ELISA). The expression of CYP11A1 was determined by quantitative real-time RT-PCR. Results: TLR9-deficient mice were resistant to chronic stress-induced lymphocyte apoptosis. In addition, in TLR9 knockout (KO) mice, chronic stress-induced upregulation of corticosterone levels was significantly decreased. Notably, lymphocytes from both TLR9 KO and wild-type mice were similarly sensitive to corticosteroid-induced cell apoptosis. Moreover, TLR9 deficiency blocked the chronic stress-induced imbalance in T helper (Th) 1 and Th2 cytokine levels. Conclusion: Taken together, our findings reveal that TLR9 plays an essential role in chronic stress-induced immune suppression.

Background: Toll-like receptors (TLRs) have been implicated in myocardial ischemia/reperfusion (I/R) injury. The TLR9 ligand, CpG-ODN has been reported to improve cell survival. We examined effect of CpG-ODN on myocardial I/R injury. Methods: Male C57BL/6 mice were treated with either CpG-ODN, control-ODN, or inhibitory CpG-ODN (iCpG-ODN) 1. h prior to myocardial ischemia (60. min) followed by reperfusion. Untreated mice served as I/R control (n. =10/each group). Infarct size was determined by TTC straining. Cardiac function was examined by echocardiography before and after myocardial I/R up to 14. days. Results: CpG-ODN administration significantly decreased infarct size by 31.4% and improved cardiac function after myocardial I/R up to 14. days. Neither control-ODN nor iCpG-ODN altered I/R-induced myocardial infarction and cardiac dysfunction. CpG-ODN attenuated I/R-induced myocardial apoptosis and prevented I/R-induced decrease in Bcl2 and increase in Bax levels in the myocardium. CpG-ODN increased Akt and GSK-3β phosphorylation in the myocardium. In vitro data suggested that CpG-ODN treatment induced TLR9 tyrosine phosphorylation and promoted an association between TLR9 and the p85 subunit of PI3K. Importantly, PI3K/Akt inhibition and Akt kinase deficiency abolished CpG-ODN-induced cardioprotection. Conclusion: CpG-ODN, the TLR9 ligand, induces protection against myocardial I/R injury. The mechanisms involve activation of the PI3K/Akt signaling pathway.

Objectives: Mental and physical stress can suppress the immune system in both humans and animals. The mechanism by which stress affects immune responses, however, remains poorly defined. Toll-like receptors (TLRs) play a key role in modulating immune responses and cell survival. The mechanisms by which TLRs modulate chronic stress are largely unexplored. Methods: Six- to 8-week-old male mice were subjected to chronic 12-hour daily physical restraint stress. Apoptotic cells were determined by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. We examined cytokine levels by enzyme-linked immunosorbent Assay (ELISA). The expression of CYP11A1 was determined by quantitative real-time RT-PCR. Results: TLR9-deficient mice were resistant to chronic stress-induced lymphocyte apoptosis. In addition, in TLR9 knockout (KO) mice, chronic stress-induced upregulation of corticosterone levels was significantly decreased. Notably, lymphocytes from both TLR9 KO and wild-type mice were similarly sensitive to corticosteroid-induced cell apoptosis. Moreover, TLR9 deficiency blocked the chronic stress-induced imbalance in T helper (Th) 1 and Th2 cytokine levels. Conclusion: Taken together, our findings reveal that TLR9 plays an essential role in chronic stress-induced immune suppression.

Background: Toll-like receptors (TLRs) have been implicated in myocardial ischemia/reperfusion (I/R) injury. The TLR9 ligand, CpG-ODN has been reported to improve cell survival. We examined effect of CpG-ODN on myocardial I/R injury. Methods: Male C57BL/6 mice were treated with either CpG-ODN, control-ODN, or inhibitory CpG-ODN (iCpG-ODN) 1. h prior to myocardial ischemia (60. min) followed by reperfusion. Untreated mice served as I/R control (n. =10/each group). Infarct size was determined by TTC straining. Cardiac function was examined by echocardiography before and after myocardial I/R up to 14. days. Results: CpG-ODN administration significantly decreased infarct size by 31.4% and improved cardiac function after myocardial I/R up to 14. days. Neither control-ODN nor iCpG-ODN altered I/R-induced myocardial infarction and cardiac dysfunction. CpG-ODN attenuated I/R-induced myocardial apoptosis and prevented I/R-induced decrease in Bcl2 and increase in Bax levels in the myocardium. CpG-ODN increased Akt and GSK-3β phosphorylation in the myocardium. In vitro data suggested that CpG-ODN treatment induced TLR9 tyrosine phosphorylation and promoted an association between TLR9 and the p85 subunit of PI3K. Importantly, PI3K/Akt inhibition and Akt kinase deficiency abolished CpG-ODN-induced cardioprotection. Conclusion: CpG-ODN, the TLR9 ligand, induces protection against myocardial I/R injury. The mechanisms involve activation of the PI3K/Akt signaling pathway.

Des lymphocytes B (LB) appelés LB régulateurs (LBreg) jouent un rôle primordial dans le contrôle de la réponse immunologique.Ces LBreg peuvent être induits suite à une stimulation. Ainsi, le Toll-like receptor (TLR) 9, récepteur de l’immunité innée, participe à cette induction. La voie de signalisation du TLR9 est déficiente chez les patients atteints de lupus érythémateux disséminé qui souffrent d’hyperinflammation chronique et dont les LBreg sont défectueux. Pour étudier le TLR9, des anticorps commerciaux sont classiquement utilisés. Parmi eux, l’anticorps monoclonal de souris anti-TLR9 26C593.2 cible un épitope présent à la membrane plasmique des LB. De plus, cet anticorps active les LB in vitro et bloque l’effet du CpG-ODN, agoniste du TLR9 endosomal. Nous montrons dans ce travail que cinq anticorps anti-TLR9 commerciaux ne sont pas spécifiques du TLR9 et reconnaissent d’autres antigènes. Quatre anticorps sont pourtant capables de reconnaître une protéine TLR9 recombinante commerciale. Afin de contourner le problème de spécificité de ces anticorps, nous avons construit un TLR9 chimérique tagué par une hémagglutinine (TLR9-HA).Trois anticorps reconnaissent cette protéine surexprimée dans des cellules transfectées.Cependant, aucun TLR9-HA ne semble être présent à la membrane plasmique des cellules transfectées. Cette approche nous a permis de démontrer que les anticorps anti-TLR9 se fixent à la membrane plasmique sur une autre cible que le TLR9. Il sera intéressant d’identifier cette protéine afin de mieux comprendre l’effet de l’anticorps anti-TLR9 monoclonal de souris sur l’activation et plus particulièrement sur l’acquisition des propriétés régulatrices des LB. / Regulatory B cells (Breg) play a key role in regulating the immunological response.This regulatory behaviour can be induced by stimulation of the B cells. Toll-like receptor 9 (TLR9), an innate immune receptor, participate to that induction. TLR9 signalling pathway is deficient in B cells from systemic lupus erythematosus patients suffering from chronic hyper-inflammation and having defective Breg cells. To study TLR9, commercial antibodies are commonly used. Among them, the anti-TLR9 monoclonal antibody 26C593.2 targets an epitope located at the plasma membrane of the B cells. Moreover, this particular antibody activates the B cells in vitro and blocks the CpGODN effects, an agonist of the endosomal TLR9. In this work, we show that five commercial antibodies are not specific for the TLR9 protein and recognize other antigens.However, four tested antibodies can recognize recombinant TLR9 molecule. In order to avoid the specificity problem, we achieved to build a chimeric TLR9 protein expressing a hemagglutinin tag at its C-terminal region (TLR9-HA). Three antibodies efficiently target this overexpressed protein in transfected cells.However, no TLR9-HA molecule seems to be located at the plasma membrane of transfected cells. This approach allowed us to demonstrate that anti-TLR9 antibodies recognize another target than TLR9. It would of interest to identify that protein in order to better understand the mouse monoclonal anti-TLR9 antibody effect on B cell activation and Breg properties.

Les cellules dendritiques plasmacytoïdes humaines (pDCs) ont été montrées comme les principales cellules productrices d'interférons de type I (IFN) suivant une stimulation de leurs récepteurs TLRs intracellulaires. Après activation, les pDCs contrôlent la localisation subcellulaire de ces TLRs menant à une production séquentielle de cytokines. Une première vague d’IFN due la voie IRF dans les endosomes précoces, suivi de la production des cytokines pro-inflammatoires due à la voie NfκB dans les endosomes tardifs. BAD-LAMP/LAMP5, membre de la famille des protéines LAMP, spécifique du cerveau chez la souris est également exprimée par les pDCs humaines. Nous révélons ici le rôle de BAD-LAMP dans la régulation du transport de TLR9 dans les pDCs. Suite à une stimulation par CpG, BAD-LAMP et TLR9 atteignent des endosomes spécialisés dans la signalisation IRF VAMP3+. Le blocage de BAD-LAMP altère le transport intracellulaire de TLR9 par sa rétention dans les endosomes VAMP3+. Alors que l’expression ectopique de BAD-LAMP accélère le transport de TLR9 dans les lysosomes LAMP1+. La rétention dans les compartiments VAMP3+ impact directement la signalisation TLR9, en augmentant la production IFN et en diminuant celle du TNFα. De plus, nous avons démontré que BAD-LAMP est régulée négativement par l’IFN. A l’inverse, les pDCs traitées avec des surnageants tumoraux ainsi que les pDCs infiltrant les tumeurs mammaires présentent à la fois un défaut dans la production d'IFN et un maintien de l’expression de BAD-LAMP. BAD-LAMP est donc un régulateur essentiel du transport de TLR9 dans les pDCs humaines qui traduit l’efficacité de la signalisation TLR9 dans des conditions pathologiques. / Human plasmacytoïd dendritic cells (pDCs) have been shown to be the principal producer of type-I interferons (IFNs) following intracellular TLRs stimulation. Upon activation, pDCs tightly control TLRs sub-cellular localization in specialized endosomes, leading to sequential programs of cytokines production: a first rapid wave of type-I IFN, due to IRF signalling from early endosomes, followed by pro-inflammatory cytokines production, dependent on NfκB signalling from late endosomal compartments. BAD-LAMP/LAMP5, an atypical member of the LAMP protein family, is brain specific in mice. In Human, BAD-LAMP is also expressed in pDCs. We reveal here a novel step of TLR regulation mediated by BAD-LAMP, that controls TLR9 access to, and signalling from, specialized subsets of endosomes in human pDCs. Upon CpG stimulation, BAD-LAMP and TLR9 follow a common endocytic sorting step, in order to reach early, IRF-signalling, VAMP3+ endosomes. BAD-LAMP silencing alters TLR9 traffic and promotes its retention in VAMP3+ endosomes, while ectopic BAD-LAMP expression triggers accelerated TLR9 transport to LAMP1+ lysosomes. Retention in VAMP3+ endosomes impacts directly on TLR9 signalling by increasing IFN production and decreasing TNFα. Importantly, we found that BAD-LAMP expression is down-regulated by IFN exposure. Conversely, pDCs treated with tumour supernatants or pDCs infiltrating human breast tumors, present both sustained BAD-LAMP expression, and defect in IFN production. BAD-LAMP is therefore an essential regulator of TLR9 transport in human pDCs and a marker of TLR9 signalling efficiency under pathological conditions.

Il est connu que les lymphocytes B (LB) ont un rôle pathogène dans de nombreuses maladies auto-immunes. Afin de comprendre comment la perte de tolérance B survient dans le lupus érythémateux systémique, maladie auto-immune prototypique, nous avons tout d’abord développé, dans un modèle murin, une méthode de marquage des LB pathogènes en cytométrie en flux. D’autre part, nous avons trouvé qu’un défaut de réponse au TLR9 est une caractéristique unique des LB de patients lupiques et est associée à une diminution d’expression du complexe CD19/CD21 à la surface des LB. Ces anomalies pourraient favoriser la survie des LB autoréactifs, et permettre la survenue de troubles auto-immuns. Dans un second temps nous avons exploré les fonctions d’une population lymphocytaire B méconnue: les LB thymiques humains. Nos résultats appuient le rôle tolérogène de ces LB, avec notamment l’expression, par 5% d’entre eux, de la protéine AIRE (AutoImmune REgulator), qui joue un rôle majeur dans la sélection négative des lymphocytes T. L’ensemble de ces données montrent la dichotomie fonctionnelle des LB et nous rappelle la complexité des processus régissant la tolérance et son maintien. / It is well known that B cells play pathogenic roles in a variety of autoimmune diseases. In order to understand how B tolerance breakdown occurs during systemic lupus erythematosus (SLE), a prototypical autoimmune disease, we first developed a method to identify autoreactive B cells by flow cytometry in a mouse model. In addition we found that a defective in vitro response to TLR9 agonists is a specific feature of SLE B cells and is associated with a CD19/CD21 complex downregulation. These abnormal functions in SLE B cells may contribute to B cell tolerance breakdown in these patients. But B-cell involvement in autoimmune diseases should not lead us to forget the functional diversity of B cells. This prompted us, in a second project, to analyze the tolerogenic role of a B cell population considered as simple bystanders of thymopoiesis: the human thymic B cells. Our results support the tolerogenic role of thymic B cells, as 5% of them express AIRE (AutoImmune REgulator), which plays a major role in cells in T cells negative selection. All these data underline the functional dichotomy of B cells and remind us the complexity of the processes governing tolerance and its maintenance.